ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AGL Angle Plc

20.75
-0.50 (-2.35%)
Last Updated: 12:42:50
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -2.35% 20.75 20.50 21.00 21.25 20.75 21.25 653,988 12:42:50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 1.04M -21.69M -0.0832 -2.49 54.07M
Angle Plc is listed in the Business Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 21.25p. Over the last year, Angle shares have traded in a share price range of 9.125p to 37.50p.

Angle currently has 260,580,547 shares in issue. The market capitalisation of Angle is £54.07 million. Angle has a price to earnings ratio (PE ratio) of -2.49.

Angle Share Discussion Threads

Showing 19376 to 19400 of 33550 messages
Chat Pages: Latest  778  777  776  775  774  773  772  771  770  769  768  767  Older
DateSubjectAuthorDiscuss
11/10/2022
11:52
amaretto1. Filtered
tday
11/10/2022
11:44
Because I'm not supposed to know ..I've added today !!
amaretto1
11/10/2022
11:41
what cant you say who is shorting it?
hsdeo
11/10/2022
11:15
You're the one losing money. Kermithttps://m.youtube.com/watch?v=5zaQgbACc1E
1liam
11/10/2022
10:56
Thats not the point muppet. I would explain but doubt your tiny brain could keep up
zeus19
11/10/2022
10:55
Won't be long Co Co
1liam
11/10/2022
10:55
It's been shorted down by ..... i do know... but can't say Andrew Newland is going to blow your balls off !!! Tight ship .. GL
amaretto1
11/10/2022
09:56
Didnt you say close below 61 yesterday. CLOWN
zeus19
11/10/2022
09:47
Into the 50s by close
1liam
11/10/2022
09:44
Far from it, that's when U buy :)Still can't work it out can you!https://m.youtube.com/watch?v=82snI2e3yEw
1liam
11/10/2022
09:35
You were a bit quite yesterday when EUA was down 12% TOOL
zeus19
11/10/2022
09:34
Amaretto adding when he said this will drop to 50p?? What a load of BS !!Feet up and relaxed EUA up 9% Have some ice ameretto dilution is coming.
1liam
11/10/2022
09:04
Give it a rest, you're becoming extremely monotonous
asdb9
11/10/2022
09:03
Yes they said that EVG ... it then went up 150 percent in one day Liam !How's your EUA ? U must be suicidal on that one guru
amaretto1
11/10/2022
08:56
In the absence of any positive news/deals I think there’s a significant drop coming for those wanting to take a punt.
antonagis
11/10/2022
08:38
Just added ... odviously red
amaretto1
10/10/2022
20:00
Whilst we're on the subject of undervalued Biotechs, what about ARIX Bioscience?

Last reported net assets of £1.78p a share made up of £130m in net cash and a further £100m in public and private investments all for a market cap of just £134m!

Just the other day the Chairman bought over £100k's worth of shares.

The reality is there has been a huge sell off in this sector and I think this has thrown up some cracking opportunities including AGL post FDA.

I'll certainly take a look at those two SK, Destiny looks particularly interesting.

arthur_lame_stocks
10/10/2022
19:48
Well,Astra Zeneca, Roche and of course Abbott are companies that I believe are key targets for Her 2 testing so interesting to see how Abbotts desire for exclusivity pans out.
jelenko
10/10/2022
19:41
Despite the price at which it was done, at least they did raise cash when needed. I can't say I'm not disappointed/surprised by the share price action (I bought some at 1.60p, although my average is a round 60p), but one has to be realistic. Yes there is much going on on corporate level, that we are not privy to, which could lead to some transformative deals, however that's the hope, meanwhile w have a market cap of some £160m, which is 'rich' for a company with low revenue growth, to date. I still maintain it will end up being bought and at around the £2.50 mark, but if they grow more incrementally, then we might not get to that sort of valuation for a year or two.

Regardless I'd rather be in that out and hold about 5% weighting here.

waterloo01
10/10/2022
19:24
With the full accreditation of the labs and the conversion of some of the 20+ customers in the pipeline this should fly again Crazy low price at the moment given the FDA approval and the fact that the nearest competitor hasn't even filed with the FDA for approvalThis is ground breaking technology. Just add a big of patiencehttps://www.sharesmagazine.co.uk/video/angle-agl-andrew-newland-chief-executive
jsforum
10/10/2022
18:35
TDay, all biotech stocks have been suffering. This is nothing specific to Angle.
Many with crazily low share prices. I could give a long list. The point being that there is nothing unique to Angle's management about the performance of the share price this year:

- Destiny Pharma, 2x Phase 3 ready drugs, expected to partner the first this quarter, valued at sub £12m per drug. Look at EVG today get a 152% rise (2.5x rise) on what was ultimately an ok licensing deal. Then look at Destiny which is ready to license and which is expected to license this quarter. It is clearly undervalued and seeing Evgen perform today bodes well for the coming weeks there, albeit it is high risk like every other biotech stock.

- RUA Life Sciences, market cap just £9m, despite having revenues of £1.625m, and being only one relatively small, confirmatory trial away from being able to make a 510k application for approval for its large bore vascular grafts (which are designed to eliminate the need for animal tissue as a sealant). The market size is $1bn/year. Its heart valve technology being developed, but an an earlier stage, is also very exciting (again using non-animal products but with none of the disadvantage of existing mechanical valves). They have been in discussions with an industry leader in heart valves to see if they can work together.

- You could add Evgen before today and look at them fly today.

The point of the above is this. You can sit here and criticise the AGL management, or those at DEST or RUA for all the mistakes they have made. No one of course is perfect. Or you can consider that the core company is very strong and take this golden opportunity to buy shares in undervalued companies at ridiculous sector low prices. And unlike the two companies above, Angle does not need cash for 2023, and it is ready to commercialise, with 20+ companies, 3 household names in contract discussions and with Abbott discussions now detailed and progressing very well, plus Baillee Gifford buying in recently at 80p and Aegon buying in since then too.

As ever dyor and aimho.

sicilian_kan
10/10/2022
18:04
Selling your shares for a Big Mac!
1liam
10/10/2022
17:28
Worrying times if this falls below 60p which now appears to be an absolute certainty in the absence of positive news/deals as I fear it will then slide quickly towards 50p or below as mentioned last week. To avoid following most other AIM stocks before it a deal or deals need to be tied up this year, that's for sure.
antonagis
10/10/2022
16:43
https://youtu.be/2Sod5qsLyhc
zeus19
10/10/2022
16:41
https://m.youtube.com/watch?v=82snI2e3yEwZOLZ
1liam
Chat Pages: Latest  778  777  776  775  774  773  772  771  770  769  768  767  Older

Your Recent History

Delayed Upgrade Clock